Introduction
- Potentially fatal complication of rheumatic diseases.
- Characterized by excessive activation and expansion of macrophages and T lymphocytes.
- Classified as secondary or reactive hemophagocytic lymphohistiocytosis.
- Produces overwhelming systemic inflammatory reaction resembling disseminated intravascular coagulation.
Epidemiology And Triggers
- Occurs most frequently in systemic juvenile idiopathic arthritis.
- Complicates 7 to 13 percent of systemic juvenile idiopathic arthritis cases overtly.
- Subclinical disease present in up to 30 percent of active systemic juvenile idiopathic arthritis patients.
- Affects 1 to 9 percent of pediatric systemic lupus erythematosus patients.
- Implicated triggers include primary rheumatic disease flares, viral infections including Epstein-Barr virus and cytomegalovirus, bacterial infections, and drug modifications.
Pathophysiology
- Marked by profound depression of natural killer cell and cytotoxic T lymphocyte function.
- Abnormal perforin expression prevents clearance of infected cells.
- Persistent antigenic stimulation drives massive expansion of T cells and macrophages.
- Escalating pro-inflammatory cytokines generate massive cytokine storm.
- Elevated interleukin-18 drives pathogenic interferon-gamma production.
- Hemophagocytic macrophages overexpress surface marker cluster of differentiation 163.
- Macrophages aggressively consume hemoglobin-haptoglobin complexes, releasing free iron.
- Ferritin excessively sequesters free iron, driving extreme hyperferritinemia.
Clinical Features
- Disease course dramatic and rapidly evolving.
- Unremitting, continuous high fever replaces typical quotidian spiking fever of active arthritis.
- Profound hepatomegaly, splenomegaly, and generalized lymphadenopathy.
- Hemorrhagic manifestations include petechiae, widespread ecchymoses, epistaxis, and gastrointestinal bleeding.
- Central nervous system involvement produces mental status changes, lethargy, seizures, and coma.
- Rapid progression to multiorgan failure, acute respiratory distress syndrome, and shock.
Laboratory Profile
- Precipitous fall in multiple blood cell lines including leukopenia, anemia, and thrombocytopenia.
- Platelet count drop typically occurs earliest.
- Paradoxical drop in erythrocyte sedimentation rate alongside persistently high C-reactive protein.
- Sedimentation rate drop driven by profound hypofibrinogenemia.
- Extreme hyperferritinemia, often exceeding 10,000 nanograms per milliliter.
- Glycosylated ferritin fraction classically falls below 20 percent.
- Coagulopathy features prolonged prothrombin time, elevated D-dimers, and consumption of clotting factors.
- Hepatic dysfunction produces highly elevated transaminases, elevated bilirubin, and raised lactate dehydrogenase.
- Elevated serum triglycerides and severe hyponatremia common.
- Bone marrow aspirates demonstrate pronounced hemophagocytosis by activated macrophages.
Diagnostic Criteria
A patient with known or suspected Systemic Juvenile Idiopathic Arthritis (sJIA) is classified as having MAS if the following criteria are met:
1. Obligatory Criterion
- Fever: Presence of a high-grade, persistent fever.
2. Laboratory Criteria (Must meet ≥ 2 of the following)
| Parameter | Threshold Value |
|---|---|
| Ferritin | > 684 ng/mL |
| Platelet Count | ≤ 181 x 10⁹/L |
| Aspartate Aminotransferase (AST) | > 48 U/L |
| Triglycerides | > 156 mg/dL (or 1.76 mmol/L) |
| Fibrinogen | ≤ 360 mg/dL |
Important Clinical Considerations
- Dynamic Nature: MAS is a rapidly evolving syndrome. A downward trend in cell counts (even if they remain within “normal” ranges) or a sudden, massive spike in ferritin is often more clinically significant than a single static value.
- HLH 2004 Criteria:While the above is specific to sJIA, the broader HLH-2004 criteria (requiring 5 out of 8 markers including splenomegaly, cytopenias, and low NK cell activity) are also frequently used for secondary MAS in other autoimmune contexts.
- Bone Marrow: Hemophagocytosis in the bone marrow is characteristic but is not required for diagnosis, as it may be absent in the early stages.
Differential Diagnosis
- Distinguishing macrophage activation from primary disease flare remains critical.
- Flare features spiking fever, increased platelet counts, increased fibrinogen, and highly elevated erythrocyte sedimentation rate.
- Must exclude severe sepsis, malignancy-associated hemophagocytosis, and drug reactions.
- Reye syndrome shares hepatic encephalopathy but lacks characteristic cytopenias.
- Thrombotic thrombocytopenic purpura features microangiopathic anemia absent in typical macrophage activation.
Management
- High mortality mandates immediate therapeutic intervention upon recognition.
- Intravenous methylprednisolone pulse therapy serves as first-line treatment.
- Administered at 30 milligrams per kilogram for 3 consecutive days.
- Transition to oral prednisolone taper at 2 to 3 milligrams per kilogram daily.
- Cyclosporine A added at 2 to 7 milligrams per kilogram daily if steroid response proves unsatisfactory within 24 to 48 hours.
- Tacrolimus serves as effective alternative calcineurin inhibitor.
- Refractory disease warrants 2004 hemophagocytic lymphohistiocytosis treatment protocol utilizing Etoposide.
- Etoposide carries severe myelosuppression and hepatic toxicity risks.
- Antithymocyte globulin offers safer alternative for patients with hepatic or renal impairment.
- Anakinra, an interleukin-1 receptor antagonist, effectively extinguishes underlying cytokine storms.
- Rituximab targets B lymphocytes, proving highly effective for Epstein-Barr virus triggered disease.
Prognosis
- Mortality rates historically approach 20 percent.
- Increasing awareness, earlier diagnosis, and aggressive targeted therapies progressively improve overall outcomes.